As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.
Wide Variation in Genomic Testing Utilization Across US, Report Finds
The report also identified opportunities to improve adoption through dissemination of evidence supporting the clinical and economic utilization of testing.
Intermountain Healthcare to Gather Utility Data as SelectHealth Covers PGx Test for Certain Employees
SelectHealth will cover PGx testing for Intermountain employees and beneficiaries with major depressive disorder who have failed treatment.
Public Awareness of Personalized Medicine Not Growing in Step With Industry, Survey Shows
Although people have greater access to personalized drugs and tests than ever before, a survey by GenomeWeb and the PMC shows public awareness isn't improving.
The year brought more FDA approvals for molecularly targeted drugs and NGS tests for personalizing cancer treatment, but reimbursement remained a stress point for industry.